AnGes Inc
Research AnGes Inc (AJW) on Bullrun: market cap EUR 63.81M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerAJW
- ExchangeF
- CountryJapan
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 63.81M
- Financial periodFY2025
- RevenueJPY 874.12M
- Revenue growth35.8%
- Net income-JPY 5.12B
- Free cash flow-JPY 5.76B
- Gross margin36.7%
Valuation Snapshot
latest market cap is EUR 63.81M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | JPY 874.12M | -JPY 5.12B | -JPY 5.76B | 36.7% | -14.44 | JPY 1.88B | JPY 54.37M | JPY 3.08B |
| FY2024 | JPY 643.64M | -JPY 28.13B | -JPY 6.69B | 38.5% | -119.53 | JPY 1.71B | JPY 272.45M | JPY 2.16B |
| FY2023 | JPY 152.99M | -JPY 7.44B | -JPY 8.84B | 12.7% | -39.29 | JPY 4.16B | JPY 362.68M | JPY 26.10B |
| FY2022 | JPY 67.06M | -JPY 14.71B | -JPY 11.23B | -40.0% | -94.29 | JPY 11.04B | JPY 1.16B | JPY 30.43B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-24 | EUR 63.81M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About AnGes Inc
AnGes, Inc. engages in the research and development of gene-based medicines. It develops HGF gene therapy product for the treatment of chronic arterial occlusive disease; NF-KB decoy oligonucleotide for chronic discogenic lumbar back pain; and DNA vaccines for the treatment of hypertension, as well as tie2 agonists for COVID-19/ARDS and drugs for chronic hepatitis B. AnGes, Inc. was formerly known as AnGes MG, Inc. and changed its name to AnGes, Inc. in July 2017.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is AnGes Inc's market cap?
AnGes Inc's market capitalization is EUR 63.81M.
What does AnGes Inc do?
AnGes, Inc. engages in the research and development of gene-based medicines. It develops HGF gene therapy product for the treatment of chronic arterial occlusive disease; NF-KB decoy oligonucleotide for chronic discogenic lumbar back pain; and DNA vaccines for the treatment of hypertension, as well as tie2 agonists for COVID-19/ARDS and drugs for chronic hepatitis B. AnGes, Inc. was formerly known as AnGes MG, Inc. and changed its name to AnGes, Inc. in July 2017. The company was incorporated in 1999 and is headquartered in Ibaraki, Japan.